Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지

The Changes of Blood Biochemical Values during Warfarin Therapy in Calves

송아지에 warfarin 투여 시에 혈액 생화학치의 변화

  • 임건태 (제주대학교 농과대학 수의학과) ;
  • 윤영민 (제주대학교 농과대학 수의학과) ;
  • 이경갑 (제주대학교 농과대학 수의학과)
  • Published : 2003.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

We executed this experiment to observe side effects of warfarin, the anticoagulant that is used for preventing thrombus in cardiovascular surgery for calves. The 6 calves(70-130 kg) were used in this experiment regardless of sexes. We administered warfarin at 0.07 mg/kg daily for 25 days. Blood was collected before warfarin administration, every five days for 30 days. PCV, RBC, WBC, fibrinogen, total protein and platelet as blood test, prothrombin time (PT) as blood coagulation test, and AST, SDH, total bilirubin, BUN and creatinine as serum biochemical tests were measured. As the result of the experiment, PT has been gradually increased after warfarin administration. It has been gradually increased and remains within the therapeutic range from the third day to the 28th day. PCV and RBC were decreased significantly from the value before the administration (p < 0.05). In the serum biochemical test, SDH shows significant increase comparing the value before the administration (p < 0.05). AST and total bilirubin were increased gradually from the value before the administration. Considering the result of the experiment, to give wafarin to prevent thrombus in cardiovascular surgery, we can get anticoagulation effect with minimal administration(0.07 mg/kg, PO) from the third day of the administration. However because of the decreased PCV and RBC, it may cause anemia. It may cause damage to liver based on the result of serum biochemical test.

Keywords

References

  1. Veterinary pharmacology and therapeutics(8th ed.) Drugs acting on blood and blood element Adams HR
  2. Methods of enzymatic analysis v.2 Gra β1 M. Samples, reagents, assessment of results Bergmeyer HU;Bergmeyer J
  3. Clin Pharm v.10 Therapy of acute thromboembolism with heparin and warfarin Carter BL
  4. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism v.4 Carter BL;Jones ME;Waickman LA
  5. South Med J v.93 no.5 Response to warfarin and other oral anticoagulants: effects of disease states Demirkan K;Stephens MA;Newman KP;Self TH https://doi.org/10.1097/00007611-200093050-00001
  6. Semi thrombo hemost v.25 no.1 Liver damage induced by coumarin anticoagulants Ehrenforth S;Schenk JF;Scharrer I https://doi.org/10.1055/s-2007-996428
  7. J Am Coll Cardiol v.23 Combined warfarin and aniplatelet therapy after St. jude medical valve replacement for mitral valve disease Hayashi J;Nakazawa S;Oguma F;Miyamura H;Eguchi S https://doi.org/10.1016/0735-1097(94)90753-6
  8. CHEST v.119 Antithrombotic therapy for venous thromboembolic disease Hyers TM;Agnelli G;Hull RD;Morris TA;Samama M;Tapson V;Weg JG https://doi.org/10.1378/chest.119.1_suppl.176S
  9. ANNA Journal v.25 no.5 Warfarin sodium(coumadin) anticoagulant therapy for vascular access patency Kinzner CL
  10. Clinical textbook for veterinary technicians(4th ed.) McCurnin DM
  11. ASAIO J v.46 Results of animal experiments using an undulation pump total artificial heart: analysis of 10 day and 19 day survival Mochizuki S;Abe Y;Chinzei T;Isoyama T;Ono T;Saito I;Guba P;Karita T;Sun YP;Kouno A;Suzuki T;Baba K;Mabuchi K;Imachi K https://doi.org/10.1097/00002480-200007000-00026
  12. Biochemi Pharmacol v.37 no.1 Warfarin: Metabolism and mode of action Park BK
  13. Ann Intern Med v.130 Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention Petty GW;Brown RD Jr;Whisnant JP;Sicks JD;O'Fallon WM;Wiebers DO https://doi.org/10.7326/0003-4819-130-1-199901050-00004
  14. Goodman & Gilman's the pharmacological basis of therapeutics(8th ed.) Philip WM;George JB Jr;Joseph PM;Douglas MT
  15. Acta Med Scand v.204 Intrahepatic jaundice due to warfarin therapy Rehnqvist N https://doi.org/10.1111/j.0954-6820.1978.tb08449.x
  16. Post Med J v.65 Control of warfarin therapy Scott DK https://doi.org/10.1136/pgmj.65.767.611
  17. Arch Intern Med v.140 Coumarin-associated hepatitis Slagboom G;Loeliger EA https://doi.org/10.1001/archinte.140.8.1028
  18. CHEST v.114 Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves Stein PD;Alpert JS;Bussey HI;Dalen JE;Turpie AGG https://doi.org/10.1378/chest.114.5_Supplement.602S
  19. ASAIO J v.46 Anticoagulation during use of a left ventricular assist device Takahama T;Kanai F;Onishi K https://doi.org/10.1097/00002480-200005000-00022
  20. Med Clin North Am v.82 no.3 Current recommendations for warfarin therapy Triplett DA https://doi.org/10.1016/S0025-7125(05)70013-4
  21. Circulation v.98 Jarvik 2000 heart potential for bridge to myocyte revovery Wesaby S;Katsumata T;Houel R;Evans R;Pigoot D;Frazier OH;Jarvik R
  22. J Am Coll Cardiol v.8 Pharmacology of heparin and warfarin Wessler S;Gitel SN https://doi.org/10.1016/S0735-1097(86)80003-1
  23. 대한외과학회지 v.54 no.1 항응고제 warfarin 복용환자에서 발생한 위장관 합병증: 공장벽 혈종 및 장중첩증 박우찬;김인철
  24. 대한신장학회지 v.14 no.4 Warfarin 과량 사용 후 발생한 Purple Toe 증후군과 동반된 급성 신부전 1예 신진호;강경원;김상목;박찬현;강종명;박한철
  25. 임상병리파일 Ⅱ판 이귀녕;이종순
  26. 수의 독성학 이창업